Table 2.

Risk stratification for biopsies following PSA and MRI during the COVID‐19 pandemic.

Risk category	PSA density (ng/mL/cc)	MRI LIKERT score	Clinical stage	Management
Green (low risk)	<0.15	2–3 No lesion	T1c to T2a	Delay biopsy, repeat PSA within the next 4‐‐6 months Low priority
Amber (intermediate risk)	<0.2	3–4–5 Lesion	>T2b N0 M0	Early biopsy, within 3 months and within 1 month Intermediate priority
Red (high risk)	>0.2	3–4–5 Lesion	≥T2c N1 M0 T3a/b N0 M0	Urgent biopsy, within 1/12 High priority

Risk category

PSA density (ng/mL/cc)

MRI LIKERT score

Clinical stage

Management

Green (low risk)

<0.15

2–3

No lesion

T1c to T2a

Delay biopsy, repeat PSA within the next 4‐‐6 months

Low priority

Amber (intermediate risk)

<0.2

3–4–5

Lesion

>T2b N0 M0

Early biopsy, within 3 months and within 1 month

Intermediate priority

Red (high risk)

>0.2

3–4–5

Lesion

≥T2c N1 M0

T3a/b N0 M0

Urgent biopsy, within 1/12

High priority